About us:

MolecularHealth is a leading

biomedical company that

is transforming molecular

data into clinically actiona-

ble information for the most

nt and safest cancer

treatment options for each

individual cancer patient.

MolecularHealth is managed

by a multidisciplinary team

of oncologists, scientists,

businesspeople, and IT ex-

perts with long-standing

expertise in th lds.

In order to continuously

adapt the feature set of

TreatmentMAP to the la-

test medical developments,

the software is constantly

being validated by means

of clinical studies.

MolecularHealth is headquar-

tered in Heidelberg, Germany

which is a European center for

biomedical cancer research.

In the USA, the company is

located in The Woodlands,

Texas, where it operates a

TreatmentMAP™

globally available biomedical and clinical knowledge.

TreatmentMAP supports physicians in optimizing their treatment decisions, even for cancer patients in advanced stages of cancer, or when all of the standard treatment options for a patient have been exhausted.

ment status of investigational drugs and the drugs and biomarkers already available on the

an essential tool for applying personalized medicine in clinical practice.

MolecularHealth constantly checks the current data available and, in a strictly quality-controlled process, enhances the TreatmentMAP software. In this way, TreatmentMAP is

• TreatmentMAP provides comprehensive information on drugs, biomarkers, diseases,

• The results of the automated analysis allow data access down to the level of the

treatment option.

TreatmentMAP uses the mostup-to-date information technology,for example, text mining and MolecularHealth’s own oncology data warehouse to comprehensivelyprioritize treatment options.

How does TreatmentMAP work?

analysis of the sequencing data from MolecularHealth.

After the tissue samples have been sequenced, the data is integrated and analyzed at

physician uses the resulting analysis to create a medical report for the treating physician

interpretation in Europe.

design, development, and production of software systems for the integrated analysis of clinical and genomic patient data to support treatment decisions and provision of related services.

• Pseudonymized patient data o ers maximum protection of the patient’s privacy.• Clinical validation in studies done together with global, well-known cancer research

centers ensure that TreatmentMAP is continuously developed and enhanced.

interpretation in Europe with direct access to the most current available biomedical knowledge

analysis of possible individual treatment options• Continuous validation in global, well-known cancer research centers to continuously

maintain the medical relevance of TreatmentMAP

Molecular Health GmbH | Kurfürsten nlage 21 | 69115 Heidelberg, Germany contact_eu@molecularhealth.com | www.molecularhealth.de

MolecularHealth works

NGS companies and global leaders in biotech and IT, including:

PM10

2